BioDelivery Sciences International

Quick facts

Phase 3 pipeline

• BEMA™ · Pain Management / Multiple therapeutic areas
  BEMA is a buccal film delivery system that rapidly dissolves in the mouth to deliver active pharmaceutical ingredients through the oral mucosa for faster systemic absorption.
• BEMA Fentanyl · Pain Management
  BEMA Fentanyl is a fentanyl formulation delivered via a buccal mucoadhesive patch that provides rapid opioid analgesia for breakthrough pain.
• DFN-15 Active · Pain Management
  DFN-15 is a buprenorphine sublingual tablet formulation designed to provide rapid onset and consistent opioid receptor agonism for pain management.
• EN3409 · Pain Management / Opioid Use Disorder
  EN3409 is a buprenorphine formulation designed to provide sustained opioid receptor agonism with reduced abuse potential through a specialized delivery technology.

Phase 1 pipeline

• Belbuca 600 µg
• Oxycodone 60 mg

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BioDelivery Sciences International portfolio CI brief
• BioDelivery Sciences International pipeline updates RSS